Health Canada to propose interim solution to close cancer drugs oversight gap

TORONTO – There may be a temporary fix to eliminate a jurisdictional grey area believed to have contributed to over 1,200 patients receiving diluted chemotherapy drugs.

Health Canada will discuss the proposal in a conference call today with top health officials from all the provinces and territories.

The goal is to close the gap between provincial and federal responsibilities over facilities that mix chemotherapy drugs for hospitals.

Marchese Hospital Solutions provided the watered down drugs to five hospitals in Ontario and New Brunswick, but officials say the company fell into a jurisdictional grey area.

A government source says Health Canada will clarify that every facility needs to be clearly identified as being under oversight of one of the jurisdictions.

Marchese has said its products weren’t defective, and has suggested that the problem wasn’t how the drugs were prepared but how they were administered at the hospitals.

“The proposal would ensure that every facility would fall under a clear oversight — be it federal or provincial — and obviously that’s important for patient care,” the source said Thursday.

Both the Ontario and federal governments have acknowledged that they don’t know how many companies like Marchese are mixing cancer drugs for hospitals with no oversight.

Too much saline was added to the bags containing cyclophosphamide and gemcitabine, in effect watering down the prescribed drug concentrations by up to 20 per cent. Some patients were taking the drugs for as long as a year.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press


The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.